retatrutide type 2 diabetes phase 2 results 2024 2025 🚨 Today, retatrutide, the GIP/GLP-1/glucagon triple agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ 💉 A triple-action once-weekly injection

Medication Safety in Breastfeeding

Aleksandr Shapsis, MD Key Takeaways: As the Tristate leader in non-surgical weight loss, EndoSlim Clinic NY is at the forefront of metabolic medicine

Retatrutide, with its triple action on GLP-1, GIP, and glucagon receptors, is the most advanced example yet

What happens if someone is undernourished after years of eating a poor diet on these appetite-suppressing drugs and then gets to the point where they can no longer obtain them

The broader guide on tirzepatide and autoimmune disease provides additional context

Timing influences: Absorption and effectiveness : When you take GLP-1 can impact how quickly it enters your bloodstream and starts working